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Abstract Insulin-stimulated DNA synthesis, M A P kinase 
(MAPK) activity and c-fos expression in vascular smooth muscle 
cells (VSMCs) was blocked by the MAPK inhibitor P D 98059. 
Regulation of c-fos expression by the transcription factor Elk-1 
at the serum response element (SRE) is dependent on its 
phosphorylation by MAPK. P D 98059 also suppressed insulin-
induced Elk-1 transcriptional activity through the SRE. These 
data show that MAPK plays a critical role in both insulin-
mediated growth and Elk-1-dependent induction of c-fos in 
VSMCs. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Hyperinsulinemia is an independent risk factor for coronary 
artery disease [1]. Insulin induces vascular smooth muscle cell 
(VSMC) proliferation, migration, and the production of ex-
tracellular matrix which are critical processes for neointima 
formation in injured vessels [2]. Activation of the E R K 1 and 
E R K 2 mitogen-activated protein kinases (MAPK) is required 
for mitogenic signaling through a number of tyrosine kinase 
growth factor receptors [3,4]. E R K s transduce mitogenic sig-
nals to the nucleus by phosphorylating and activating specific 
transcription factors, such as Elk-1, which induce expression 
of c-fos and other early growth response genes that control 
the transition from quiescence to proliferation [5,6]. 
N o study to date has examined the role of the M A P K 
pathway in insulin-stimulated V S M C growth. We have re-
cently shown that M A P K plays a central role in P D G F -
and All-directed migration [6,7] and bFGF-induced prolifer-
ation [8] in rat VSMCs. These growth factors, like insulin, 
have been implicated in promoting lesion development by 
enhancing V S M C growth, migration, and matrix production 
[9,10]. In the present study, the importance of M A P K in 
VSMCs is further extended by our findings that this pathway 
is required for insulin-stimulated D N A synthesis and Elk-1-
mediated c-fos activation in VSMCs. 
*Corresponding author. Fax: (1) (310) 794-7654. 
2. Materials and methods 
2.1. Cell culture 
Rat aortic smooth muscle cells were prepared from thoracic aorta 
of 2-3 month old Sprague-Dawley rats using the explant technique 
[11]. The cells were cultured in DMEM containing 10% FBS, 150 mM 
HEPES, 100 U/ml penicillin, 100 ug/ml streptomycin and 200 mM 
glutamine (Sigma, St. Louis, MO). The purity and identity of the 
smooth muscle cell cultures were verified using a monoclonal antibody 
against smooth muscle a-actin (Sigma). For all experiments, early 
passaged (8 or less) rat VSMCs were grown to 60-70% confluence 
and made quiescent by serum starvation for at least 24 h, when 
MAPK activity was assayed. For all data shown, each individual 
experiment represented in the n value was performed using an inde-
pendent preparation of VSMC. 
2.2. VSMC DNA synthesis 
Incorporation of the thymidine analogue, bromodeoxyuridine 
(BrdU), was measured to determine the effect of insulin on DNA 
synthesis as described previously [8]. VSMCs were plated out at 
3.0 X101 cells on 24 well plates (Falcon primaria) in DMEM with 
10% FBS for 48 h. After serum starvation for 24 h in DMEM con-
taining 0.1% FBS, cells were incubated with insulin (Eli Lilly, Indian-
apolis, IN) in the presence or absence of PD 98059 (1-30 uM), for the 
next 20 h. When present, PD 98059 was added 30 min prior to insulin 
stimulation and maintained throughout the incubation. Then BrdU at 
15 \xM (Sigma) was added, and the incubation continued for another 
4 h. BrdU-positive cells were visualized using BrdU monoclonal anti-
body (Zymed, San Francisco, CA) followed by the ABC method. 
BrdU-positive cell nuclei were counted in 4-6 different high power 
fields/well and related to total cell number/high power field. 
2.3. MAP in-gel kinase assay 
MAPK activity was measured by the in-gel kinase assay as de-
scribed previously [8]. PD 98059 (New England Biolabs) was given 
30 min before inducing MAPK activation with insulin for 10 min and 
was present throughout the incubation period. For the data shown, 
each individual experiment represented in the n value was performed 
using an independent preparation of VSMCs. Densitometric analysis 
was performed using NIH Image 1.60 software on a Macintosh PC. 
2.4. Isolation and analysis of RNA 
Total RNA was isolated from VSMCs using guanidinium-isothio-
cyanate followed by phenol-chloroform extraction [12]. RNA was 
size-fractionated by electrophoresis through a denaturing 1% agarose 
gel, transferred to nitrocellulose membranes, and hybridized with 
cDNA probes labeled with [32P]dCTP (3000 Ci/mmol) by random 
priming. The cDNA for c-fos was from Jill Norman (UCLA School 
of Medicine). The hybridization signals of the specific mRNAs of 
interest were normalized to those of CHOB to correct for differences 
in loading or transfer. CHOB cDNA was originally isolated from 
Chinese hamster ovary cells and corresponds to a mRNA ubiqui-
tously expressed in mammalian tissues which does not exhibit regu-
lation as a function of growth or development [13]. Quantitation of 
Northern blots was performed by densitometric analysis using NIH 
Image 1.60 software for Macintosh personal computers. Several auto-
radiographic film exposures were used to ensure that the density of 
the signals were linear on each film. 
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2.5. Transfections 
VSMCs were transfected with 15 ug of SRE-CAT reporter plasmid, 
or 7.5 ug of the Gal-Elk-1 expression vector and 7.5 ug Gal4-CAT 
reporter plasmid, or 7.5 ug of the mutant Gal-ElklAA expression 
vector and 7.5 ug Gal4-CAT reporter plasmid and 5 ug of pCHHO 
(SV40 (3-galactosidase reference plasmid) using a calcium phosphate 
transient transfection kit (Stratagene, La Jolla, CA) as reported else-
where [8]. After transfection, cells were starved for 24 h before stim-
ulation with insulin for 6 h. PD 98059 was added 30 min prior to the 
addition of insulin. Lysates were prepared and normalized for protein 
content using the Lowry method. Chloramphenical acetyltransf erase 
(CAT) and P-galactosidase assays were performed using standard 
methods [14,15]. All experiments were performed in duplicate and 
repeated at least three times to ensure reproducibility. CAT activities 
were corrected for transfection efficiency by assaying extracts for P-
galactosidase activity. 
2.6. Statistical analysis 
Analysis of variance, paired or unpaired Mest, were performed for 
statistical analysis, as appropriate. P values less that 0.05 were con-
sidered to be statistically significant. Data are expressed as mean± 
S.E.M. 
3. Results 
3.1. Inhibition of MAPK activation with PD 98059 blocks 
insulin-induced DNA synthesis 
MAPK is phosphorylated and activated by MEK (MAPK-
extracellular signal regulated kinase kinase), a dual specificity 
kinase that phosphorylates serine and tyrosine residues [3,4]. 
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Fig. 1. The MAPK pathway inhibitor PD 98059 blocks insulin-
stimulated DNA synthesis in VSMCs. Cells were made quiescent by 
incubation for 24 h in DMEM containing 0.1% FBS. To measure 
DNA synthesis, cells were stimulated with insulin for 24 h; 15 uM 
BrdU was present for the fin al 4h. The percentage of cells incorpo-
rating BrdU is expressed as the meani S.E.M. A: Dose response 
for insulin-stimulated DNA synthesis (« = 4, *P<0.01 vs. unstimu-
lated control). B: Dose-dependent inhibition of DNA synthesis by 
PD 98059 in VSMCs stimulated with 1 uM insulin (» = 4, P<0.01 
vs. 1 uM insulin alone). 
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Fig. 2. Insulin stimulates MAPK in VSMCs which is inhibited by 
PD 98059. Quiescent cells were stimulated with 1 uM insulin for 10 
min prior to stimulation. Cell extracts were prepared and equal 
amounts of protein (10 ug/lane) were separated on a 10% PAGE-
SDS gel with 0.4 mg/ml myelin basic protein (MBP). In-gel kinase 
renaturation assays were performed and bands corresponding to the 
44-kDa (ERK1) and 42-kDa (ERK2) MAPKs were visualized by 
the phosphorylation of MBP. A representative autoradiogram is de-
picted. Densitometric analysis was performed on in-gel kinase assays 
from four separate experiments and are expressed as arbitrary 
units±S.E.M. (n = 4, */,<0.01 vs. unstimulated control; P<0.01 
vs. insulin alone). 
PD 98059 is a highly selective inhibitor of MEK commonly 
used to block MAPK activation [16]. VSMCs were made qui-
escent by 16 h treatment in medium containing 0.1% serum. 
Exposure to insulin for 20 h induced a concentration-depend-
ent increase in DNA synthesis (P< 0.01 at 0.1 and 1 uM, Fig. 
1A). The addition of PD 98059 30 min prior to insulin treat-
ment (1 uM) and its presence throughout the incubation peri-
od resulted in a dose-dependent inhibition of insulin-stimu-
lated DNA synthesis. The insulin-mediated increase in DNA 
synthesis was completely suppressed by 30 uM PD 98059 
(P<0.01 vs. 1 uM insulin alone, Fig. IB). These data dem-
onstrate that mitogenic signaling by insulin in VSMCs is to-
tally MAPK-dependent. 
3.2. Insulin-induced MAPK activity in VSMCs is inhibited by 
PD 98059 
Quiescent VSMCs exhibited very low MAPK activity, as 
evidenced by the faint signals produced by the phosphoryla-
tion of substrate myelin basic protein by ERK1 (p44) and 
ERK2 (p42) MAPKs in the in-gel kinase assay (Fig. 2). 
VSMC treated with 1 uM insulin for 10 min displayed a 
strong induction of ERK1 and ERK2 activity ( ~ 4-fold, 
Fig. 2). Insulin-induced MAPK activity was inhibited in a 
concentration-dependent manner by PD 98059. At 30 uM 
PD 98059, the insulin-induced activation of ERK1 plus 
ERK2 MAPKs was abolished (« = 4, P<0 .01 vs. insulin 
alone). These data corroborate that mitogenic signaling by 
insulin in VSMCs is MAPK-dependent since both insulin-in-
duced DNA synthesis and MAPK activation are completely 
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Fig. 3. PD 98059 inhibits induction of c-fos mRNA by insulin (1 
|j,M). Quiescent cells were stimulated in the presence or absence of 
PD 98059 as in Fig. 2. RNA was isolated 30 min after stimulation 
with insulin and subjected to Northern analysis. 20 |xg of RNA 
were loaded per lane and blots were hybridized with 32P-labeled 
DNAs for c-fos and CHOB, a mRNA from a housekeeping gene 
used to normalize for equivalent RNA loading and transfer. De-
picted is an autoradiogram which is representative of four independ-
ent experiments that were performed. 
inhibited by the MAPK pathway inhibitor PD 98059 (com-
pare Figs. 1 and 2). 
3.3. Insulin-induced c-fos expression is inhibited by PD 98059 
Induction of c-fos transcription is a paradigm for the nu-
clear effects of MAPK signaling that lead to cell proliferation 
[17]. Quiescent VSMCs do not express detectable c-fos mRNA 
by Northern analysis (Fig. 3). Treatment with 1 |a,M insulin 
for 30 min produces a strong induction of c-fos mRNA. Pre-
treatment of VSMCs with PD 98059 for 30 min and its in-
clusion throughout the incubation period resulted in a dose-
dependent inhibition of insulin-induced c-fos expression (Fig. 
3). At 30 \iM PD 98059 insulin-induced c-fos expression was 
almost completely suppressed. 
3.4. PD 98059 blocks insulin-induced transactivation of the 
serum response element (SRE) by Elk-1 
Insulin-induced transcriptional activation of the c-fos gene 
is mediated by transcription factors which bind to the SRE 
located in the c-fos 5'-flanking DNA [18]. The transcription 
factor Elk-1 activates c-fos expression through the SRE and 
this activity is dependent on its phosphorylation by MAPK 
[5]. The data in Fig. 4 demonstrate that insulin-stimulated 
transactivation of SRE is through the MAPK pathway. 
VSMCs were transiently transfected with 2x-SRE-CAT re-
porter plasmids. Addition of 1 |xM insulin resulted in an in-
crease in CAT activity relative to unstimulated transfectants. 
Insulin-stimulated SRE-CAT activity was reduced to levels 
detected in unstimulated cells by the addition of either 10 
uM or 30 uM PD 98059 to suppress MAPK signaling. 
MAPK-dependent Elk-1-specific transactivation can be 
quantitatively measured by transfection of an expression vec-
tor which produces a chimeric transcription factor composed 
of the N-terminal binding domain of the yeast GAL4 protein 
and the C-terminal transactivation domain of Elk-1 [5]. The 
GAL-Elk-1 expression vector is cotransfected with a reporter 
construct containing four copies GAL4 DNA-binding sites to 
which the GAL-Elk-1 fusion protein binds and directs CAT 
transcription from a thymidine kinase minimal promoter. 
Stimulation of quiescent VSMCs cotransfected with GAL-
Elk-1 and GAL-CAT plasmids with 1 U.M insulin resulted in a 
5-fold increase in GAL-CAT activity (P<0.01 vs. unstimu-
lated cells, Fig. 5). Insulin-induced GAL-CAT activity was 
completely abolished by 30 uM PD 98059. The presence of 
+ PD98059 + PD9SPM 
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Fig. 4. PD 98059 inhibits insulin-induced transcriptional activation 
of a SRE. VSMCs were transfected with SRE-CAT plasmid and 
made quiescent as described in Section 2. CAT activity was meas-
ured 6 h after stimulation with 1 uM insulin in the presence or ab-
sence of PD 98059. Data are expressed as % of insulin-stimulated 
CAT activity (100%), after normalization to co-transfected pCHHO 
(3-galactosidase activity. Data are from three separate experi-
ments ± S.E.M. 
PD 98059 alone had no effect on basal GAL-CAT activity. 
The MAPK dependence of insulin-induced GAL-CAT activ-
ity was verified by transfecting the expression plasmid GAL-
Elk-1 AA in which the C-terminal MAPK phosphorylation 
sites have been deleted [19]. Treatment with 1 LIM insulin 
failed to stimulate GAL-CAT activity in VSMCs cotrans-
fected with GAL-Elk-1 AA. 
In combination, the data in Figs. 4 and 5 demonstrate that 
insulin-induced c-fos expression through the SRE is dependent 
on the phosphorylation of Elk-1 by MAPK. 
4. Discussion 
Hyperinsulinemia in diabetic patients may contribute to the 
development of atherosclerosis in this population through the 
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Fig. 5. Activation of Elk-1 by insulin is MAPK-dependent. Cells 
were co-transfected with GAL4-CAT reporter plasmid and either 
GAL-Elk-1 or GAL-Elk-IAA vectors, which express chimeric tran-
scription factors containing or lacking Elk-1 MAP phosphorylation 
sites, respectively. Quiescent transfected cells were stimulated with 
1 U.M insulin in the presence or absence of PD 98059 for 6 h. Data 
are expressed as the fold increase of insulin-stimulated CAT activity 
over unstimulated controls after normalization to P-galactosidase ac-
tivity ±S.E.M. (« = 4, *P<0.01 vs. unstimulated controls; P<0.01 
vs. insulin alone). 
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mitogenic effect of insulin on VSMCs [20]. Understanding 
mitogenic signaling by insulin in VSMCs, therefore, is impor-
tant since this may lead to identification of new targets for 
pharmacologic intervention to ameliorate diabetes-associated 
vascular disease. 
Rat VSMCs express both insulin and insulin-like growth 
factor-I (IGF-I) receptors [21]. Insulin and IGF-I each pro-
mote VSMC growth, although the latter is a more potent 
mitogen. Mitogenic signaling by insulin has been studied pri-
marily in non-vascular cells; rat fibroblast cells overexpressing 
transfected human insulin receptors being frequently studied 
as a model system [22]. In these cells, both insulin-induced 
DNA synthesis and c-fos expression were shown to be de-
pendent on the activation of phosphatidylinositol 3-kinase 
(PI3-kinase), based on microinjection of neutralizing antibody 
[23,24] or treatment with the PI3-kinase inhibitors wortman-
nin [24]. Similarly, fibroblasts from insulin receptor substrate-
1 (IRS-1) knockout mice fail to activate PI3-kinase in re-
sponse to IGF-I which is paralleled by a decrease in IGF-I 
stimulated DNA synthesis and c-fos induction [25]. 
In combination, the above studies demonstrate that activa-
tion of PI3-kinase is necessary, at least in some cell types, for 
mitogenic signaling by insulin and IGF-1. Although the RAS-
-> RAF -> MEK -> MAPK cascade has been implicated in ty-
rosine kinase growth factor receptor-mediated cell prolifera-
tion [3,4], no study has directly assessed the role of this 
pathway in insulin-stimulated mitogenesis. We have used 
PD 98059 to inhibit the phosphorylation and activation of 
MAPK by MEK. Treatment of VSMCs with PD 98059 re-
sulted in a dose-dependent inhibition of both insulin-stimu-
lated DNA synthesis and MAPK activation. Inhibition of 
insulin-induced mitogenic signaling is likely due to the disrup-
tion of MAPK-mediated nuclear events, which include the 
induction of the growth-associated gene c-fos by the 
MAPK-regulated transcription factor Elk-1. The observed ef-
fects of insulin may be mediated in part through IGF-1 re-
ceptors activated by the relatively high levels of hormone used 
in these experiments. Since both insulin and IGF-I have been 
shown to activate MAPK in non-vascular cells [26], we antici-
pate that PD 98059 will have a similar effect on either path-
way. 
Our data provide the first evidence that the MAPK path-
way is necessary for insulin to function as a VSMC mitogen. 
This finding appears to be in conflict with prior studies in 
fibroblasts showing that insulin-stimulated growth is PI3-kin-
ase-dependent, since that pathway is generally considered to 
be a post-receptor branch separable from the MAPK cascade. 
Our results can potentially be harmonized with findings made 
in fibroblasts for the following reasons: (1) signaling pathways 
critical for insulin-mediated mitogenesis may be cell-type spe-
cific and different in fibroblasts versus VSMCs; (2) studies 
with fibroblasts demonstrated only that the PI3-kinase path-
way was necessary for insulin mitogenic signaling; they did 
not preclude a requirement for additional pathways; and (3) 
recent data have suggested potential cross-talk between the 
PI3-kinase and MAPK pathways, since phosphoinositide 
products of PI3-kinase increase activity of PKC£ which can 
activate RAF or MEK [27,28]. 
MAPK has been previously shown to be required for 
PDGF- [29], bFGF- [8], and All-stimulated growth [7], as 
well as for PDGF- and All-directed migration [6,7] in 
VSMCs. The present finding that VSMC growth in response 
to insulin is also MAPK-dependent provides additional sup-
port for the central role of this pathway in regulating VSMC 
growth and migration. Pharmacological intervention targeting 
MAPK, therefore, may represent a novel therapeutic strategy 
for the treatment of vascular disease driven by multiple 
growth factors, including insulin. 
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